Develops a topical small molecule treatment that reactivates dormant hair follicle stem cells by targeting a unique metabolic switch, restoring the body’s natural hair growth capacity. This approach addresses hair loss conditions like androgenetic alopecia, offering a non-invasive alternative to existing therapies with limited efficacy and invasive procedures.
Funding
$30.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current hair loss treatments, such as anti-androgen drugs, minoxidil, and platelet-rich plasma (PRP), often exhibit limited efficacy, unclear mechanisms of action, and are not universally suitable due to invasiveness or systemic side effects. Many available options lack FDA approval and may not be effective for all genders, skin types, or hair types. Hair follicle stem cells can become dormant due to age, stress, hormones, and chemotherapy, preventing hair growth.
Solution
Pelage Pharmaceuticals is developing a topical small molecule drug platform designed to reactivate dormant hair follicle stem cells, addressing hair loss at its source. The treatment targets a unique metabolic switch within hair follicles, stimulating robust hair growth without invasive procedures or systemic exposure. By focusing on the intrinsic metabolic properties of hair follicle stem cells, Pelage's platform aims to provide a solution suitable for all genders, skin types, and hair types. The drug restores the regenerative capacity of the follicle, triggering new hair growth by overcoming the dormancy of hair follicle stem cells.
Target Audience
The primary target audience includes individuals experiencing hair loss conditions such as androgenetic alopecia (male and female pattern baldness), chemotherapy-induced hair loss, and telogen effluvium, seeking a non-invasive and universally applicable treatment.
Features
- Topical small molecule drug designed for non-invasive application.
- Targets the metabolic switch in hair follicle stem cells to stimulate activation.
- Designed to be effective for androgenetic alopecia, chemotherapy-induced hair loss, and telogen effluvium.
- Suitable for all genders, skin types, and hair types.
- Phase 2a clinical trials are in progress (ClinicalTrials ID NCT06393).
- Aims to restore the natural regenerative capacity of hair follicles.
- Selected publications in American Academy of Dermatology 2024 Annual Meeting, Experimental Dermatology, and Nature Cell Biology.